文献リスト

1）Folkman J. Tumor angiogenesis: therapeutic impli­cations. N Engl J Med. 1971; 285: 1182-6

2）Herbst RS. Therapeutic options to target angioge­nesis in human malignancies. Expert Opin Emerg Drugs. 2006; 11: 635-50

3）Panares RL, Garcia AA. Bevacizumab in the mana­­ge­­­ment of solid tumors. Expert Rev Anti­cancer Ther. 2007; 7: 433-45

4）Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8: 299-309

5）Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003; 111: 1287-95

6）Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy. 2007; 27: 1125-44

7）Kulimova E, Oelmann E, Bisping G, et al. Growth inhibition and induction of apoptosis in acute mye­loid leukemia cells by new indolinone deri­vatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors. Mol Cancer Ther. 2006; 5(12): 3105-12

8）Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained rece­ptor blockade and good antitumor efficacy. Can­cer Res. 2008; 68(12): 4774-82

9）Roth GJ, Heckel A, Colbatzky F, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem. 2009; 52(14): 4466-80

10）Antoniu SA, Kolb MR. Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis. IDrugs. 2010; 13(5): 332-45

11）Gori B, Ricciardi S, Fulvi1 A, et al. New anti­angiogenics in non-small cell lung cancer treatment: VargatefTM (BIBF 1120) and beyond. Ther Clin Risk Manag. 2011; 7: 429-40

12）Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010; 35(3): 496-504

13）King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011; 378: 1949-61

14）Allen JT, Spiteri MA. Growth factors in idiopathic pulmonary fibrosis: relative roles. Respir Res. 2002; 3: 13

15）Abdollahi A, Li M, Ping G, et al. Inhibition of platelet-derived growth factor signaling attenu­ates pulmonary fibrosis. J Exp Med. 2005; 201: 925-35

16）Yu C, Wang F, Jin C, et al. Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis. Am J Pathol. 2003; 163: 1653-62

17）Hamada N, Kuwano K, Yamada M, et al. Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J Immunol. 2005; 175: 1224-31

18）Aono Y, Nishioka Y, Inayama M, et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med. 2005; 171: 1279-85

19）Chaudhary NI, Schnapp A, Park JE. Pharmaco­logical differentiation of inflammation and fibro­sis in the rat bleomycinmodel. Am J Respir Crit Care Med. 2006; 173: 769-76

20）Daniels CE, Lasky JA, Limper AH, et al; Imatinib-IPF Study Investigators. Imatinib treat­ment for idiopathic pulmonary fibrosis: Rando­mized placebo-controlled trial results. Am J Respir Crit Care Med. 2010; 181: 604-10

21）Chaudhary NI, Roth GJ, Hilberg F, et al. Inhi­bition of PDGF, VEGF and FGF signaling attenu­ates fibrosis. Eur Respir J. 2007; 29: 976-85

22）Richeldi L, Costabe U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pul­mo­nary fibrosis. N Engl J Med. 2011; 365: 1079-87

23）Stopfer P, Rathgen K, Bischoff D, et al. Phar­macokinetics and metabo­lism of BIBF 1120 after oral dosing to healthy male volunteers. Xeno­biotica. 2011; 41(4): 297-311

24）Reck M. BIBF 1120 for the treatment of non-small cell lung cancer. Expert Opin Investig Drugs. 2010; 19(6): 789-94

25）Mross KB, Gmehling D, Frost A, et al. A clinical, phase I pharmacokinetic (PK) and pharmacody­namics study of twice-daily BIBF 1120 in advanced cancer patients. J Clin Oncol. 2005; 23: 3031

26）Okamoto I, Kaneda H, Satoh T, et al. 2010. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhi­bitor in patients with advanced solid tumors. Mol Cancer Ther. 2010; 9(10): 2825-33

27）du Bois A, Huober J, Stopfer P, et al. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and car­bop­latin in patients with advanced gynecological malignancies. Ann Oncol. 2010; 21(2): 370-5

28）Bousquet G, Alexandre J, Le Tourneau C, et al. Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients. Br J Cancer. 2011; 105: 1640-5

29）Ellis PM, Kaiser R, Zhao Y, et al. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemet­rexed in pretreated non–small cell lung cancer patients. Clin Cancer Res. 2010; 16: 2881-9

30）Reck M, Kaiser R, Eschbach C, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhi­bitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol. 2011; 22: 1374-81

31）吾妻安良太，谷口博之，井上義一，他．日本人IPFにおけるBIBF1120（B）とPirfenidone（P）併用投与の安全性，忍容性，薬物動態を検討する臨床試験　第52回呼吸器学会総会発表．日呼吸誌．2012; 1: 125

32）Herbst RS. Toxicities of antiangiogenic therapy in nonsmall-cell lung cancer. Clin Lung Cancer. 2006; 8 Suppl 1: S23-30

33）ClinicalTrials.gov. LUME-Lung 1: BIBF 1120 plus­docetaxel as compared to placebo plus docetaxel in 2nd line non small cell lung cancer. 2008. Avail­able from: http://clinicaltrials.gov/ct2/show/NCT00805194? term=BIBF+1120&rank=6. Acce­ssed October 5, 2012

34）ClinicalTrials.gov. LUME-Lung 2: BIBF 1120 plus pemetrexed compared to placebo plus pemetrexed in 2nd line nonsquamous NSCLC. 2008. Avail­able from: http://clinicaltrials.gov/ct2/show/NCT00806819?intr=%22BIBF++1120%22&phase=2&rank=1. Accessed October 5, 2012

35）ClinicalTrials.gov. Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibro­sis Patients 2011. Available from: http://clinical­trials.gov/ct2/show/NCT01335464?intr=%22BIBF++1120%22&phase=2&rank=3. Accessed October 5, 2012

36）ClinicalTrials. gov. Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibro­sis PatientsⅡ 2011. Available from: http://clinical­trials.gov/ct2/show/NCT01335477?intr=%22BIBF++1120%22&phase=2&rank=4. Accessed October 5, 2012

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp